Crispr Therapeutics AG vs Tractor Supply Co — how do they compare? Crispr Therapeutics AG trades at $53.83 (market cap $5.23B), while Tractor Supply Co trades at $35.62 (market cap $18.39B). The key difference: Tractor Supply Co is far larger — about 3.5× Crispr Therapeutics AG's market cap, and Tractor Supply Co pays a 2.72% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TSCO | |
|---|---|---|
Market Cap | $5.23B | $18.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $62.65 |
52-Week Low | $44.34 | $29.14 |
Enterprise Value | $3.65B | $24.70B |
Dividend Yield | — | 2.72% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
TSCO trades at $34.62, up 0.17% today, with a bullish technical signal from moving averages but bearish oscillators. The stock has missed earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue has grown steadily from $14.2B in 2022 to $15.5B in 2025, though net income margin has declined. Recent news highlights cost pressures and a lowered 2026 outlook, alongside strategic initiatives like pet product expansion and dividend payments.
The outlook is mixed: a consensus price target of $36.29 suggests modest upside, but near-term headwinds from weak discretionary demand and higher costs pose risks. Long-term opportunities include digital growth and store investments, yet investor sentiment remains cautious amid earnings misses and guidance cuts.
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →